Association of LINC00673 rs11655237 polymorphism with cancer susceptibility: A meta-analysis based on 23,478 subjects

Genomics. 2020 Nov;112(6):4148-4154. doi: 10.1016/j.ygeno.2020.07.015. Epub 2020 Jul 8.

Abstract

Background: Some studies on the relationship between LINC00673 polymorphism and cancer susceptibility have been inconsistent. To perform a more comprehensively quantitative assessment of LINC00673 rs11655237 and risk of overall cancer, we operated this meta-analysis for the first time.

Methods: A comprehensive search was conducted to obtain relevant literature up to November 20, 2019. Pooled odds ratios and 95% confidence intervals were utilized to assess rs11655237 and cancer susceptibility under five different genetic models.

Results: Eventually, 11 case-control studies from 9 articles were included. We found that LINC00673 rs11655237 polymorphism increased the susceptibility to overall cancer under all genetic models in the overall population. By dividing ethnicity and cancer type into subgroups, we also obtained similar positive results in subgroups of Chinese population, pancreatic cancer, cervical cancer, neuroblastoma, hepatoblastoma and gastric cancer.

Conclusion: Overall, this meta-analysis has demonstrated for the first time that LINC00673 rs11655237 could increase susceptibility to cancer.

Keywords: Cancer; LINC00673; Meta-analysis; Polymorphism; Susceptibility; rs11655237.

Publication types

  • Meta-Analysis
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Case-Control Studies
  • Genetic Predisposition to Disease*
  • Humans
  • Neoplasms / genetics*
  • Polymorphism, Genetic*
  • RNA, Long Noncoding / genetics*

Substances

  • RNA, Long Noncoding
  • long non-coding RNA SLNCR1, human